CA Patent

CA3110346A1 — Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses

Assigned to Esperion Therapeutics Inc · Expires 2020-02-27 · 6y expired

What this patent protects

Disclosed herein are compositions comprising fixed doses of ETC-1002, ezetimibe, and statin, and methods of treating subjects comprising adminstering fixed doses of ETC-1002, ezetimibe, and statin. Also disclosed herein are methods for administering fixed doses of ETC-1002 or eze…

USPTO Abstract

Disclosed herein are compositions comprising fixed doses of ETC-1002, ezetimibe, and statin, and methods of treating subjects comprising adminstering fixed doses of ETC-1002, ezetimibe, and statin. Also disclosed herein are methods for administering fixed doses of ETC-1002 or ezetimibe or both to statin-intolerant patients or patients receiving statin therapy, wherein the administration reduces the likelihood of worsening diabetes in the subject or increasing the likelihood of new onset diabetes in a subject. The methods disclosed herein also include methods of treating hypercholesterolemia and cardiovascular diseases in a subject.

Drugs covered by this patent

Patent Metadata

Patent number
CA3110346A1
Jurisdiction
CA
Classification
—
Expires
2020-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Esperion Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.